EPAA at the 12th World Congress

The World Congress on Alternatives and Animal Use in the Life Sciences (WC series) was established by the Alternatives Congress Trust in Baltimore, USA in 1993.

It brings together multidisciplinary stakeholders from academia, industry, government, and non-profit sectors under 1 roof to advance the 3Rs —  reduce, refine, and replace the use of animals in the life sciences.

In 2023, the WC12 will be held in Niagara Falls, Canada from 27-31 August with the following contributions from EPAA below.

EPAA Oral presentations

• Tuesday, 29 August 

11:00 – 12:30: Session S429 - A World of 3R Centres: Unity in Diversity

#679 The European Partnership for Alternative Approaches to Animal Testing (EPAA): Accelerating the Transition to Animal-Free, Sustainable Innovation. Gavin Maxwell^1,2, Charles Laroche^2,3, Irene Manou², Pascale Oosterbosch^2,4, Dorota Przyludzka^2,4, Zvonimir Zvonar², Giacomo Mattino’^2,4. (¹Unilever; ²EPAA; ³AISE; ⁴DG GROW, European Commission)

• Wednesday, 30 August

11:00 – 12:30: Session S410 - NAMs in Practice: Fit-for-Purpose NGRA Across Sectors

#361 EPAA Project: Use of New Approach Methodologies (NAMs) in regulatory decisions for chemical safety. Pilar Prieto¹, Carl Westmoreland², Catherine Mahony³, Gavin Maxwell², Irene Manou⁴, Charles Laroche⁵ (¹European Commission, Joint Research Centre; ²Unilever, SEAC; ³Procter and Gamble Technical Centre Ltd; ⁴EPAA Industry Secretariat; ⁵AISE)

16.30 – 17.30: EPAA 2023 Student grants winner

EPAA 3Rs student grants help researchers participate in high-profile, international meetings that focus on the development and acceptance of 3R alternatives to animal testing (replacement, reduction or refinement).

This year, one super grant of €2 500 for the 12th World Congress on Alternatives and Animal Use in Life Sciences was available. The winner of the super grant is Prem Chad for his poster Characterization of Hepatic 3D Spheroids Using Multiphoton Microscopy and OMICS.

EPAA Poster Presentations

Theme: regulatory acceptance and global harmonisation

Poster board no. A30

Abstract #560

Re-evaluating the need for chronic toxicity studies with therapeutic monoclonal antibodies, using a weight of evidence approach.

Sewell F¹, Chien H², Prior H¹, Schutte K³, Weir L⁴, van Meer P²

1 NC3Rs, UK

2 Medicines Evaluation Board, Netherlands

3 European Commission Joint Research Centre, Belgium

4 GSK, UK

Poster board no. A31

Abstract #: 443

New data supporting recognition of evident toxicity in Acute Oral toxicity studies (OECD TG 420)

Fiona Sewell¹, David Andrew², Marco Corvaro³, Irene Manou⁴, Boris Mueller⁵, Tim Rowan⁴, Graham Horgan⁶, Ian Ragan⁷

1 National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs)

2 ERM 3 Corteva 4 EPAA 5 Symrise 6 BIOSS 7 Independent

Theme: regulatory acceptance and global harmonisation

Poster board no. A45

Abstract #: 603

The future of pyrogenicity testing: phasing out the rabbit pyrogen test

Katrin Schutte1, Emmanuelle Charton2, Gwenael Cirefice2

¹ European Commission ² European Directorate for the Quality of Medicines & HealthCare

The full WC12 programme is available on the conference website.